🇺🇸 FDA

Intelligence · Clinical Pipeline

Anaxis Pharma Pipeline

All ClinicalTrials.gov programs at Anaxis Pharma — phase, modality, and trial IDs.

Programs
642

Quick answer

Anaxis Pharma has 642 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. A Phase 1 Open-Label Mass Balance clinical trial to Investigate the Absorption, Metabolism, and Excretion of Single Oral Administration of [14C]-TEV-56286 Following Multiple Oral Administrations of Nonlabeled TEV-56286 to Healthy Male Participants.

    Lacuna Pharma Pty Ltd

    Healthy participant

    phase 1 other active

    1 trial

  2. A Phase 1 Safety and Dose Finding Study of 131I -TLX101 Plus Standard of Care in Patients with Newly Diagnosed Glioblastoma

    Lacuna Pharma Pty Ltd

    Glioblastoma multiforme (GBM)

    phase 1 other active

    1 trial

  3. A Phase 1 relative bioavailability study in 14 healthy adult participants investigating the Arvisol® tablets to see whether its pharmacokinetic properties are similar to the reference drug which is a marketed oral soliton cannabidiol, named Epidiolex® CBD oral solution.

    Lacuna Pharma Pty Ltd

    Healthy volunteers

    phase 1 other active

    1 trial

  4. A Phase 1, Dose-Escalating, Randomized, Placebo-Controlled, 4-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of COR-1167 in Healthy Subjects and Subjects with Chronic Heart Failure (CHF)

    Lacuna Pharma Pty Ltd

    Chronic heart failure

    phase 1 other active

    1 trial

  5. A Phase 1, Double-blind, Randomized, Three-arm, Parallel Group Study to Compare the Pharmacokinetics and Safety of a Single Subcutaneous Dose of PBP1502, EU-Humira®, and US-Humira® in Healthy Male and Female Subjects

    Lacuna Pharma Pty Ltd

    Healthy volunteers

    phase 1 other active

    1 trial

  6. A Phase 1, Open-Label, 2-Period, 2-Formulation, Within-Subject Crossover Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose Level of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Human Subjects Under Fasting Conditions.

    Lacuna Pharma Pty Ltd

    not applicable (submitted trial is a pharmacokinetic and pharmacodynamic safety study in healthy subjects)

    phase 1 other active

    1 trial

  7. A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pimozide after Multiple Dose Administration in Subjects with Rheumatoid Arthritis

    Lacuna Pharma Pty Ltd

    rheumatoid arthritis

    phase 1 other active

    1 trial

  8. A Phase 1, Randomized, Double-Blind, Two-Arm, Two-Way Crossover Study of Pharmacokinetics and Pharmacodynamics of QL0911

    Lacuna Pharma Pty Ltd

    Immune Thrombocytopenia, Hematopoietic Syndrome of Acute Radiation Syndrome

    phase 1 other active

    1 trial

  9. A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma

    Lacuna Pharma Pty Ltd

    Mantle Cell Lymphoma

    phase 1 other active

    1 trial

  10. A Phase I Randomized, Single-center, Double-blind, Two-period Crossover Trial to Evaluate Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR4 Compared with Insulin Icodec in Participants with Type 2 Diabetes.

    Lacuna Pharma Pty Ltd

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  11. A Phase I study of STA551 and STA551 in combination with atezolizumab in patients with solid tumours

    Lacuna Pharma Pty Ltd

    Locally advanced or metastatic solid tumors

    phase 1 other active

    1 trial

  12. A Phase I study to evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult Subjects

    Lacuna Pharma Pty Ltd

    Severe infections caused by Gram-negative bacteria

    phase 1 other active

    1 trial

  13. A Phase I trial to investigate the pharmacokinetics and ECG effects of single doses of linaprazan glurate administered as oral tablets to healthy participants

    Lacuna Pharma Pty Ltd

    Erosive Gastroesophageal Reflux Disease (eGERD)

    phase 1 other active

    1 trial

  14. A Phase I, open-label study in healthy adults comparing the availability in the body of the active substance lidocaine following administration of 2% and 4% lidocaine gel into the urethra

    Lacuna Pharma Pty Ltd

    bioavailability trial with healthy participants, therapeutic indication not studied

    phase 1 other active

    1 trial

  15. A Randomized Study in Healthy Participants to Identify the Optimal Subcutaneous Injection Strategy for COR-1167

    Lacuna Pharma Pty Ltd

    Chronic Heart Failure

    phase 1 other active

    1 trial

  16. A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavailability at Steady-State of LY03010 versus XEPLION® in Patients with Schizophrenia

    Lacuna Pharma Pty Ltd

    Schizophrenia

    phase 1 other active

    1 trial

  17. A SINGLE-CENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF REPEAT DOSES OF ARM210 IN HEALTHY SUBJECTS.

    Lacuna Pharma Pty Ltd

    Cardiac arrhythmias

    phase 1 other active

    1 trial

  18. A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF COR-1389

    Lacuna Pharma Pty Ltd

    Obesity / Right heart failure (healthy participants)

    phase 1 other active

    1 trial

  19. A Single Dose, Fast state, Crossover Replicate Bioequivalence Study of NITROFURANTOIN 100 mg prolonged-release capsules (IASIS PHARMA) vs.FURABID® 100 mg prolonged-release capsules (Amdipharm Limited)

    Lacuna Pharma Pty Ltd

    healthy subjects

    phase 1 other active

    1 trial

  20. A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants with Solid Cancers Treated with Cemiplimab

    Lacuna Pharma Pty Ltd

    Advanced Solid Tumor

    phase 1 other active

    1 trial

  21. A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected Melanoma

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 1 other active

    1 trial

  22. A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Multiple Myeloma

    phase 1 other active

    1 trial

  23. A Study to Learn More About an Investigational Medicine called HDP-102 in Patients with Relapsed/Refractory B-cell Blood Cancers.

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory B-cell Malignancies

    phase 1 other active

    1 trial

  24. A Trial to Evaluate Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR4 Compared with Insulin Degludec and Insulin Icodec in Participants with Type 2 Diabetes

    Lacuna Pharma Pty Ltd

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  25. A Trial to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Insulin GZR33 Compared with Insulin Degludec at steady state in participants with Type 1 Diabetes

    Lacuna Pharma Pty Ltd

    Type 1 diabetes Mellitus

    phase 1 other active

    1 trial

  26. A clinical trial to learn how an investigational drug (MP-101) affects on the laboratory signs of the disease when given to Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease (AD) patients

    Lacuna Pharma Pty Ltd

    Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD)

    phase 1 other active

    1 trial

  27. A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine Delayed Release Tablets USP 1.2 g manufactured by Sun Pharmaceutical Industries Limited, India with Mezavant (mesalamine) Delayed and Extended-Release Tablets 1.2 g product of Takeda Canada Inc., in healthy, adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    ulcerative colitis

    phase 1 other active

    1 trial

  28. A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine Delayed Release Tablets USP 1.2 g manufactured by Sun Pharmaceutical Industries Limited, India with Mezavant (mesalamine) Delayed and Extended-Release Tablets 1.2 g product of Takeda Canada Inc., in healthy, adult, human subjects under fed condition.

    Lacuna Pharma Pty Ltd

    ulcerative colitis

    phase 1 other active

    1 trial

  29. A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Bupropion Hydrochloride Sustained-Release Tablets 150 mg, manufactured for Sun Pharmaceutical Industries Limited, India with PrOdan Bupropion SR (Bupropion Hydrochloride Sustained-Release Tablets 150 mg), product of Odan Laboratories Ltd., 325 Stillview Avenue, Pointe Claire, Quebec, H9R 2Y6, in healthy adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    major depressive illness

    phase 1 other active

    1 trial

  30. A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Bupropion Hydrochloride Sustained-Release Tablets 150 mg, manufactured for Sun Pharmaceutical Industries Limited, India with PrOdan Bupropion SR (Bupropion Hydrochloride Sustained-Release Tablets 150 mg), product of Odan Laboratories Ltd., 325 Stillview Avenue, Pointe Claire, Quebec, H9R 2Y6, in healthy adult, human subjects under fed condition.

    Lacuna Pharma Pty Ltd

    major depressive illness

    phase 1 other active

    1 trial

  31. A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Lisdexamfetamine Dimesylate capsules 10 mg, manufactured by Ohm Laboratories Inc. (A Sun Pharma Company), 14 Terminal Road, New Brunswick, 08901, NJ, USA with Vyvanse (Lisdexamfetamine Dimesylate) 10 mg capsules; Product of Takeda Canada Inc., Toronto Ontario ON M5H 4E3, Canada, in healthy adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    ADHD

    phase 1 other active

    1 trial

  32. A drug-drug interaction trial in healthy female participants to investigate the effect of aprocitentan on combined hormonal contraceptives.

    Lacuna Pharma Pty Ltd

    Not applicable - healthy volunteer trial

    phase 1 other active

    1 trial

  33. A phase 1, Pharmacokinetic Comparison of Vonafexor Acid and Its Lysine Salt (EYP651) and Evaluation of Potential Drug-Drug Interactions.

    Lacuna Pharma Pty Ltd

    Healthy volunteers, Impaired renal function and suspected MASH

    phase 1 other active

    1 trial

  34. A phase 1, randomised, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics in healthy adult subjects after subcutaneous injection of TISA-818-Inj-5mg/mL.

    Lacuna Pharma Pty Ltd

    Idiopathic pulmonary fibrosis

    phase 1 other active

    1 trial

  35. A phase 1, randomized, double-blind, single-center, placebo-controlled first-in-human trial to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of RBD7007 in healthy participants

    Lacuna Pharma Pty Ltd

    Complement-mediated diseases

    phase 1 other active

    1 trial

  36. A randomised, double-blind, placebo-controlled phase Ib trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ACD856 in healthy participants

    Lacuna Pharma Pty Ltd

    Depression, Cognitive dysfunction, Alzheimer’s disease

    phase 1 other active

    1 trial

  37. A randomised, double-blind, placebo-controlled trial to assess the effects of EP395 following an inhaled endotoxin challenge in healthy adults

    Lacuna Pharma Pty Ltd

    Healthy volunteers [targeted indication: chronic obstructive pulmonary disease (COPD)]

    phase 1 other active

    1 trial

  38. A randomised, open-label, 5-period, cross-over trial to assess the pharmacokinetics and safety of 3 oral solid formulations of buloxibutid (C21) in healthy male and female participants

    Lacuna Pharma Pty Ltd

    Idiopahtic pulmonary fibrosis

    phase 1 other active

    1 trial

  39. A randomised, open-label, single-centre, drug-drug-interaction trial to evaluate the impact of carboxylesterase 2 (CES2)- and CYP3A4-inhibition on the pharmacokinetics of buloxibutid in healthy volunteers

    Lacuna Pharma Pty Ltd

    Idiopathic pulmonary fibrosis

    phase 1 other active

    1 trial

  40. A randomized double-blind placebo-controlled phase 1 study on the safety, tolerability and pharmacokinetics/-dynamics of escalating single intravenous doses of AK1967 (Procizumab) in healthy male volunteers

    Lacuna Pharma Pty Ltd

    Circulatory shock

    phase 1 other active

    1 trial

  41. A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing apixaban 5 mg hard capsules (PG412 [Celon Pharma]) vs apixaban 5 mg film-coated tablets (Eliquis [Bristol-Myers Squibb]) under fasting conditions in healthy volunteers

    Lacuna Pharma Pty Ltd

    Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

    phase 1 other active

    1 trial

  42. A randomized, open-label, single dose, cross-over study to evaluate the drug-drug interaction between Proscar 5 mg, film-coated tablets and Cialis 5 mg film-coated tablets when co-administered versus the administration of each product alone in healthy volunteers under fasting conditions. Study no. FIN-TAD-DDI-03-24

    Lacuna Pharma Pty Ltd

    healthy male subjects

    phase 1 other active

    1 trial

  43. A randomized, single dose, cross-over, replicated, open-label bioequivalence study comparing indacaterol/glycopyrronium (85/43mcg inhalation powder hard capsules) (PG341 [Celon Pharma] vs Ultibro Breezhaler [Novartis])

    Lacuna Pharma Pty Ltd

    Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)

    phase 1 other active

    1 trial

  44. A randomized, single-blind, placebo-controlled, study to examine the safety, tolerability, and pharmacokinetics of M6229 administered as a 120-hour continuous infusion at two dose levels versus placebo in healthy subjects

    Lacuna Pharma Pty Ltd

    Sepsis and Septic Shock

    phase 1 other active

    1 trial

  45. A randomized, two-way, crossover, two parallel groups study to compare the bioavailability of 150 mg and 300 mg trazodone hydrochloride tablets (new polymer) (Angelini Pharma S.p.A.) vs. 150 mg and 300 mg trazodone hydrochloride Contramid® tablets (Angelini Pharma S.p.A.) at steady-state

    Lacuna Pharma Pty Ltd

    Intended indication: Major Depressive Disorders with and without anxiety, Healthy volunteers, therapeutic indication not studied

    phase 1 other active

    1 trial

  46. A single dose, randomized, double-blind 2-arm parallel-group study to compare the pharmacokinetics, immunogenicity, and safety for PB016 versus US-licensed Entyvio® after subcutaneous administration in healthy participants

    Lacuna Pharma Pty Ltd

    Not applicable, healthy volunteers

    phase 1 other active

    1 trial

  47. A single-dose, randomized, two-period, two-sequence, crossover comparative bioavailability study on formulations containing ramipril, amlodipine and indapamide in combination product versus Triatec® 10 mg capsules (Sanofi - Produtos Farmacêuticos, Lda., Portugal), containing ramipril, Norvasc® 10 mg, tablets (Upjohn EESV, the Netherlands), containing amlodipine and Natrilix® 2.5 mg film-coated tablets (Les Laboratoires Servier, France), containing indapamide co-administered together as reference in healthy

    Lacuna Pharma Pty Ltd

    hypertension

    phase 1 other active

    1 trial

  48. A study comparing the new drug PG413 produced by Celon Pharma SA with the drug Eliquis available on the market in healthy volunteers.

    Lacuna Pharma Pty Ltd

    Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

    phase 1 other active

    1 trial

Frequently asked questions

How many pipeline programs does Anaxis Pharma have?

642 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.